# Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

> **NCT00953862** · NA · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 18 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine

## Key facts

- **NCT ID:** NCT00953862
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00953862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00953862, "Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00953862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*